Recipharm sees H1 sales bump; Valeant pours $142M into plant; Aurobindo hits FDA issues;

> Swedish CDMO Recipharm said its sales were up 46% in H1 to about €185 million ($203 million). Report

> Valeant ($VRX) spent $142 million in the second quarter on restructuring work at a Bausch + Lomb plant in Waterford, Ireland. Release

> Aurobindo plant in India received an FDA Form 483. Report

> Federal officials have extracted a guilty plea and $450,000 in penalties from U.S.-based Aracoma Drug Company, a pharmacy that sold drugs over the Internet that had not been legally prescribed. Report